PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 13.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 173,841 shares of the company's stock after purchasing an additional 20,835 shares during the quarter. Victory Capital Management Inc. owned approximately 0.31% of PROCEPT BioRobotics worth $10,128,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. FMR LLC lifted its stake in shares of PROCEPT BioRobotics by 11.9% in the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after purchasing an additional 866,328 shares during the last quarter. Vanguard Group Inc. lifted its stake in PROCEPT BioRobotics by 6.1% during the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after acquiring an additional 297,075 shares in the last quarter. Alliancebernstein L.P. lifted its stake in PROCEPT BioRobotics by 14.2% during the 4th quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock worth $141,110,000 after acquiring an additional 218,148 shares in the last quarter. Wellington Management Group LLP lifted its stake in PROCEPT BioRobotics by 38.8% during the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after acquiring an additional 416,819 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in PROCEPT BioRobotics by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock valued at $93,751,000 after purchasing an additional 57,449 shares in the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Bank of America reduced their price target on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Friday, April 25th. Wall Street Zen lowered PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research report on Saturday, July 12th. Morgan Stanley reduced their price target on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 15th. Truist Financial cut their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Finally, Stephens started coverage on PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an "overweight" rating and a $70.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus price target of $84.13.

PROCEPT BioRobotics Stock Down 5.0%

Shares of NASDAQ PRCT traded down $2.92 during midday trading on Friday, hitting $55.72. 3,891,204 shares of the company's stock were exchanged, compared to its average volume of 840,729. The company has a market cap of $3.08 billion, a PE ratio of -32.78 and a beta of 1.07. PROCEPT BioRobotics Corporation has a twelve month low of $47.04 and a twelve month high of $103.81. The firm's fifty day simple moving average is $59.01 and its 200-day simple moving average is $61.36. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.95 and a quick ratio of 7.75.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04. The company had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 28.09% and a negative net margin of 36.20%. The firm's revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.51) earnings per share. Research analysts predict that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 25,000 shares of PROCEPT BioRobotics stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the transaction, the director owned 14,363 shares of the company's stock, valued at $883,180.87. The trade was a 63.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 100,000 shares of company stock worth $6,271,250 over the last quarter. Insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).